ISSN - | E-ISSN -2822-2288
Eurasian Journal of Medical Advances
Eplerenone (Mineralocorticoid Receptor Antagonist) Induced Bilateral Gynecomastia [EJMA]
EJMA. 2022; 2(3): 146-147 | DOI: 10.14744/ejma.2022.42714

Eplerenone (Mineralocorticoid Receptor Antagonist) Induced Bilateral Gynecomastia

Weng Chio Tam, Màrio Évora
Department of Cardiology, Centro Hospitalar Conde São Januário, Macao SAR

Mineralocorticoid receptor antagonist (MRA) is also known as potassium-sparing diuretics which is commonly used for the treatment of heart failure and hypertension. Spironolactone is the first generation of MRA but it may have some adverse effects, particularly gynecomastia. This adverse effect may be related to its properties of androgen suppression. In contrast to spironolactone, eplerenone is the second generation of MRA which may be less potent in blocking the activation of androgen receptors resulting in less gynecomastia. However, despite limited sexual and hormonal side effects, we should still keep cautious regarding the anti-androgen effect of eplerenone. In this report, we demonstrated one 88-year-old male patient with eplerenone induced gynecomastia.

Keywords: Eplerenone, gynecomastia, mineralocorticoid receptor antagonist

Weng Chio Tam, Màrio Évora. Eplerenone (Mineralocorticoid Receptor Antagonist) Induced Bilateral Gynecomastia. EJMA. 2022; 2(3): 146-147

Corresponding Author: Weng Chio Tam, China
Manuscript Language: English